CAR T-Cell Therapy in Hematologic Malignancies

This CME program at Hospital HIMA, Bistro Tartine, will provide perspectives on the latest data on the use of CAR T-Cell (Chimeric Antigen Receptor T-Cell) therapies for hematologic malignancies, focusing on FDA approved indications and its future role.

FRIDAY, APRIL 29, 2022
5:00–6:30 p.m.

Hospital HIMA
Bistro Tartine
500 Ave. Degetau, HIMA Plaza 1 | Caguas, 00725, Puerto Rico
Presented in Spanish (slides will be in English)

SPEAKER
Julio Chávez, MD, MS
Associate Member,
Lymphoma Section,
Department of Malignant Hematology
Moffitt Cancer Center

Learning Objectives:
• Evaluate the latest clinical safety and efficacy data guiding the selection and sequencing of CAR T-cell therapy based on disease, treatment, and patient factors
• Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia, B-cell lymphomas, or myeloma to improve outcomes and enhance survivorship
• Describe the toxicities associated with CAR T-cell therapy
• Explain the post CAR T-cell therapy care

To register for this complimentary, limited seating program, click here: https://cvent.me/Y7bn5Y

Questions? Contact:
Marina.Delgadillo@Moffitt.org
813-745-4798

ACCREDITATION
This activity has been approved for AMA PRA Category 1 Credits™